Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. reports developments tied to its robotic surgery technology, financial results, and public-company status. The company is developing the Vicarious Surgical System for minimally invasive surgery, with updates covering benchtop and in-vivo testing, surgical instruments for ventral hernia repair, software engineering support, and progress toward system validation and clinical readiness.
Company news also covers operating expense trends, research and development spending, cash-burn discipline, and capital markets actions involving its Class A common stock. Recent disclosures include quotation on the OTCQB market after NYSE suspension and filings related to stockholder approval of a potential reverse stock split.
Vicarious Surgical Inc. announced the resignation of board members Dror Berman and Samir Kaul effective October 18, 2022. The company appointed Beverly Huss to the board on the same date, where she will serve on the Audit Committee. Huss brings extensive experience in medical devices and has previously held CEO positions at companies like Pagonia Medical and Qool Therapeutics. The company aims to enhance surgical procedures through innovative robotic technology.
Vicarious Surgical Inc. (RBOT) has announced a Demonstration Day for its Beta 2 surgical robot prototype, scheduled for December 6, 2022, at 11:00 a.m. ET in Waltham, MA. The event is exclusive, with limited in-person attendance by invitation only, but will be live-streamed for broader access. The company aims to enhance surgical efficiency and patient outcomes through innovative robotics technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 11:30 am ET. The virtual event aims to highlight emerging growth companies. Vicarious Surgical focuses on enhancing surgical efficiency and patient outcomes through advanced robotic technology. A live webcast will be available through a provided link, with an archived version accessible on their investor website following the event.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its Q2 2022 financial results, revealing a significant increase in operating expenses to $19.1 million, up from $6.6 million in Q2 2021. Adjusted net loss rose to $19.1 million, or $0.16 per share, compared to a loss of $6.6 million or $0.08 per share in the previous year. The company is advancing its Beta 2 system and partnering with UH Ventures and HCA Healthcare for surgical innovations. Cash burn rate for the quarter was $15.7 million. A conference call will be held today at 4:30 p.m. ET.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) has announced its participation in the Canaccord Genuity 42nd Annual Growth Conference set for Wednesday, August 10 at 9:30 a.m. ET. A live webcast of the presentation will be available on the company’s website, with an archive for later viewing. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is pioneering robotic technology aimed at enhancing surgical efficiency and patient outcomes while reducing healthcare costs.
Vicarious Surgical Inc. (NYSE: RBOT) will report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call, open to investors, will begin at 4:30 p.m. Eastern Time. The company, founded in 2014, focuses on developing advanced robotics for minimally invasive surgery, aiming to enhance efficiency and reduce healthcare costs. Vicarious Surgical is backed by notable investors, including Bill Gates and Vinod Khosla, and is headquartered in Waltham, Massachusetts.
Vicarious Surgical has entered into Center of Excellence agreements with HCA Healthcare and University Hospitals Ventures. These partnerships aim to enhance the design and commercialization of the Company's robotic surgical system, incorporating real-world feedback from surgeons and healthcare administrators. This collaboration provides Vicarious Surgical with critical insights into surgical workflows, promoting the system's readiness for FDA approval. The partnerships are viewed as significant validation of its in-hospital potential, positioning Vicarious Surgical for future growth in the competitive healthcare market.
Vicarious Surgical Inc. (NYSE: RBOT) will be added to the Russell 3000®, Russell 2000®, and Russell Microcap® Indexes following the annual reconstitution on June 27, 2022. This inclusion recognizes the company as one of the 4,000 largest U.S. stocks based on market capitalization. CEO Adam Sachs expressed that this milestone will enhance institutional visibility and engagement. Russell indexes, which are benchmarks for approximately $12 trillion in assets, offer a significant platform for investors.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Cowen 7th Annual FutureHealth Conference. Management will present on June 22 at 10:50 a.m. ET, and a live webcast will be accessible on the company’s website. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical develops advanced robotics technology aimed at improving patient outcomes and reducing healthcare costs through minimally invasive surgeries.
Vicarious Surgical announced its financial results for Q1 2022, reporting a substantial increase in operating expenses to $18.2 million from $5.2 million in Q1 2021, marking a 248% rise. R&D costs rose to $9.8 million, while general and administrative expenses reached $6.9 million. The adjusted net loss was $18.2 million, or $0.15 per share, compared to a loss of $5.2 million, or $0.06 per share, in the previous year. Notably, GAAP net income was $42.5 million, translating to net income per share of $0.35. The company continues to advance its Vicarious System with successful beta testing.